Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass

References

• CummingsSRMeltonLJEpidemiology and outcomes of osteoporotic fracturesLancet20023591761176712049882
   PubMed Web of Science ®Google Scholar
• Consensus Development Conference 1991. Prophylaxis and treatment of osteoporosisAm J Med1991901071101986575
   PubMed Web of Science ®Google Scholar
• NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and TherapyJAMA200128578579511176917
   PubMed Web of Science ®Google Scholar
• RiggsBLMeltonLJIIIThe worldwide problem of osteoporosis: Insights afforded by epidemiologyBone199517Suppl 5S505S511
   PubMed Web of Science ®Google Scholar
• BurgeRTDawson-HughesBSolomonDIncidence and economic burden of osteoporotic fractures in the United States, 2005–2025J Bone Miner Res20073446547517144789
   PubMed Web of Science ®Google Scholar
• WHO Scientific Group on the Assessment of Osteoporosis at the Primary Health Care LevelSummary meeting reportProceedings of the World Health Organization Meeting5–7 May 2004Brussels, Belgium Available from: http://www.who.int/chp/topics/Osteoporosis.pdfAccessed March 7 2010
   Google Scholar
• World Health OrganizationCollaborating Centre for Metabolic Bone DiseasesFRAX^® WHO fracture risk assessment tool Available from: http://www.shef.ac.uk/FRAX®/tool.jsp?locationValue=9.Accessed March 7, 2010
   Google Scholar
• National Osteoporosis FoundationClinician’s Guide to Prevention and Treatment of OsteoporosisWashington DCNational Osteoporosis Foundation2010 Available from: www.nof.org/physguideAccessed March 7, 2010
   Google Scholar
• American Orthopaedic AssociationOwn the Bone.™Rosemont, ILAmerican Orthopaedic Association Available from: http://www.ownthebone.org/providersAccessed March 7, 2010
   Google Scholar
• CarmonaRAdachiRTreatment of postmenopausal osteoporosis, patient perspectives – focus on once yearly zoledronic acidPatient Pref Adherence20093189193
   Web of Science ®Google Scholar
• LewieckiEMA clinician’s perspective on the use of zoledronic acid in the treatment postmenopausal osteoporosisJ Clin Densitom20081147848418757222
   PubMed Web of Science ®Google Scholar
• SirisESSelbyPOLSaagKGImpact of osteoporosis treatment adherence on fracture rates in North America and EuropeAm J Med2009122Suppl 2AS3S1319187810
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human ServicesBone health and osteoporosis: A report of the Surgeon GeneralUS Department of Health and Human Services, Office of the Surgeon GeneralRockville, MD [updated 2004 October 14]. Available from: http://www.surgeongeneral.gov/library/bonehealth/Accessed March 7, 2010.
   Google Scholar
• McClungMReckerRMillerPIntravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronateBone20074112212817468062
   PubMed Web of Science ®Google Scholar
• DeeksEDPerryCMZoledronic acid: A review of its use in the treatment of osteoporosisDrugs Aging20082596398618947264
   PubMed Web of Science ®Google Scholar
• DemontieroODuqueGOnce-yearly zoledronic acid in hip fracture preventionClin Interv Aging20094153164
   Web of Science ®Google Scholar
• ColeREHarrisTPreventing nonvertebral osteoporotic fractures with extended-interval bisphosphonates: Regimen selection and clinical applicationMedscape J Med.2009 [serial online]1112 Available from: http://search.medscape.com/medscape-search?queryText=preventing%20nonvertebral;Accessed March 7, 201019295933
   PubMedGoogle Scholar
• FardellonePCortetBLegrandECost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosisJoint Bone Spine201077535720034831
   PubMed Web of Science ®Google Scholar
• PerazellaMAMarkowtizGSBisphosphonate nephrotoxicityKidney Int2008741385139318685574
   PubMed Web of Science ®Google Scholar
• Reclast [Package insert]Novartis PharmaceuticalsEast Hanover, NJ May2009 http://www.pharma.us.novartis.com/product/pi/pdf/reclast.pdfAccessed March 7 2010
   Google Scholar
• LambrinoudakiIVlachouSGalapiFOnce-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal womenClin Interv Aging20083445451
   Web of Science ®Google Scholar
• KavanaghKLGuoKDunfordJEThe molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugsProc Natl Acad Sci U S A20061037829783416684881
   PubMed Web of Science ®Google Scholar
• DelmasPDMunozFBlackDMEffects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosisJ Bone Miner Res2009241544155419338427
   PubMed Web of Science ®Google Scholar
• ReckerRRDelmasPDHalseJEffects of intravenous zoledronic acid once yearly on bone remodeling and bone structureJ Bone Miner Res20082361617892374
   PubMed Web of Science ®Google Scholar
• BlackDMDelmasPDEastellROnce-yearly zoledronic acid for treatment of postmenopausal osteoporosisN Engl J Med200735618091822
   PubMed Web of Science ®Google Scholar
• BoonenSBlackDMColon-EmericCSEfficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and olderJ Amer Geriatr Soc20105829229920070415
   PubMed Web of Science ®Google Scholar
• MacLeanCNewberrySMaglioneMSystematic review: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosisAnn Intern Med200814819721318087050
   PubMed Web of Science ®Google Scholar
• BilezikianJPEfficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosisAm J Med.2009122Suppl 2S14S2119187808
   PubMed Web of Science ®Google Scholar
• ReidDMDevogelaerJPSaagKHORIZON investigatorsZoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): A multicenter, double-blind, double-dummy, randomized controlled trialLancet20093731253126319362675
   PubMed Web of Science ®Google Scholar
• LylesKWColon-EmericCSMagazinerJSZoledronic acid and clinical fractures and mortality after hip fractureN Engl J Med20073571799180917878149
   PubMed Web of Science ®Google Scholar
• EriksenEFLylesKWColon-EmericCSAntifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fractureJ Bone Miner Res2009241308131319257818
   PubMed Web of Science ®Google Scholar
• CompstonJTreatments for osteoporosis – looking beyond the HORIZON [Editorial]N Engl J Med.356181878188017476015
   PubMed Web of Science ®Google Scholar
• PiperPKJrGruntmanisUManagement of osteoporosis in the aging male: Focus on zoledronic acidClin Interv Aging2009428930319750231
   PubMed Web of Science ®Google Scholar
• Biannnual IV zoledronic acid (Reclast) for prevention of osteoporosisThe Medical Letter: On Drugs and Therapies200951131549 Available from: www.medicalletter.orgAccessed March 7, 2010
   Google Scholar
• McClungMMillerPRecknorCZoledronic acid for the prevention of bone loss in postmenopausal women with low bone massObstet Gynecol2009114999100720168099
   PubMed Web of Science ®Google Scholar
• BrufskyAMZoledronic acid for cancer therapy-induced and postmenopausal bone lossExpert Opin Pharmacother200891013102818377343
   PubMed Web of Science ®Google Scholar
• DoggrellSAClinical efficacy and safety of zoledronic acid in prostate and breast cancerExpert Rev Anticancer Ther200991211121819761424
   PubMed Web of Science ®Google Scholar
• PolascikTJMouravievVZoledronic acid in the management of metastatic bone diseaseTherap Clin Risk Manag2008426126818728715
   PubMedGoogle Scholar
• BodyJJBergmannPBoonenSManagement of cancer treatment-induced bone loss in early breast and prostate cancer – a consensus paper of the Belgian Bone ClubOsteoporos Int2007181439145017690930
   PubMed Web of Science ®Google Scholar
• BrufskyAMBossermanLDCaradonnaRRZoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST Study 36-month follow-up resultsClin Breast Cancer20099778519433387
   PubMed Web of Science ®Google Scholar
• HinesSLSloanJAAthertonPJZoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapyBreast201019929620079640
   PubMed Web of Science ®Google Scholar
• HershmanDLMcMahonDJCrewKDZoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancerJ Clin Oncol2008264739474518711172
   PubMed Web of Science ®Google Scholar
• GnantMMlineritschBLuschin-EbengreuthGAdjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone mineral density substudyLancet Oncol2008984084918718815
   PubMed Web of Science ®Google Scholar
• BundredNJCampbellIDDavidsonNEffective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study resultsCancer20081121001101018205185
   PubMed Web of Science ®Google Scholar
• BhoopalamNCampbellSCMoritzTIntravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapyJ Urol20091822257226419758618
   PubMed Web of Science ®Google Scholar
• IsraeliRSRosenbergSJSaltzsteinDRThe effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapyClin Genitourin Cancer2007527127717553207
   PubMed Web of Science ®Google Scholar
• MichaelsonMDKaufmanDSLeeHRandomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancerJ Clin Oncol2007251038104217369566
   PubMed Web of Science ®Google Scholar
• RyanCWHuoDBylowKSuppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acidBJU Int2007100707517552955
   PubMed Web of Science ®Google Scholar
• SmithMREasthamJGleasonDMRandomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancerJ Urol20031706 Pt 123922393
   Web of Science ®Google Scholar
• CrawfordBALKamCPavlovicJZoledronic acid prevents bone loss after liver transplantation: A randomized, double-blind, placebo-controlled trialAnn Int Med200614423924816490909
   PubMed Web of Science ®Google Scholar
• HamdyRCKrishnaswamyGCancellaroVChanges in bone mineral content and density following strokesAm J Phys Med Rehabil1993721881918363812
   PubMed Web of Science ®Google Scholar
• HamdyRCMooreSWCancellaroVALong term effects of strokes on bone massAm J Phys Med Rehabil1995743513567576411
   PubMed Web of Science ®Google Scholar
• PooleKESLoveridgeNRoseCMA single infusion of zoledronate prevents bone loss after strokeStroke2007381519152517395868
   PubMed Web of Science ®Google Scholar
• HuangJMeixnerLFernandezSA double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosisAIDS200923515719050386
   PubMed Web of Science ®Google Scholar
• BerensonJRYellinOBocciaRVZoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone lossClin Cancer Res2008146289629518829511
   PubMed Web of Science ®Google Scholar
• OtrockZKAzarSTShamseddeenWAIntravenous zoledronic acid treatment in thalassemia-induced osteoporosis; results of a phase II clinical trialAnn Hematol20068560560916830143
   PubMed Web of Science ®Google Scholar
• VoskaridouEAnagnostopoulousAKonstantopoulousKZoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: Results from a single-center, randomized, placebo-controlled trialHaematologica2006911193120216956818
   PubMed Web of Science ®Google Scholar
• PerifanisVVyzantiadisTTziomalosKEffect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemiaAnn Hematol200786233017013645
   PubMed Web of Science ®Google Scholar
• OlsonKVan PoznakCSignificance and impact of bisphosphonate induced acute phase responsesJ Oncol Pharm Pract20071322322918045781
   PubMedGoogle Scholar
• PapapetrouPDBisphosphonate-associated adverse eventsHormones200989611019570737
   PubMedGoogle Scholar
• KennelKADrakeMTAdverse effects of bisphosphonates: Implications for osteoporosis managementMayo Clin Proc20098463263819567717
   PubMed Web of Science ®Google Scholar
• WysowskiDKChangJTAlendronate and risedronate: Reports of severe bone, joint and muscle painArch Intern Med200516534634715710802
   PubMedGoogle Scholar
• US Food and Drug AdministrationBisphosphonates (marketed as Actonel, Actonel + Ca, Aredia Boniva Didronel Fosamax Fosamax + D Reclast Skelid, and Zometa) Available from: http://www.fda.medwatch/safety/2008/safety08.htm#BisphosphonatesAccessed March 7 2010
   Google Scholar
• de Torrente da la JaraGPecoudAFavratBMusculoskeletal pain in female asylum seekers and hypovitaminosis D3BMJ200432915615715258072
   PubMedGoogle Scholar
• Gwynne JonesDPSavageRLHightonJAlendronate induced synovitisJ Rheumatol20083553753818203307
   PubMed Web of Science ®Google Scholar
• Werner de CastroGRNevesFSde MagalhaesSouzaFialhoSCFlare-up of hand osteoarthritis caused by zoledronic acid infusionOsteoporos Int Nov 212009 [Epub ahead of print]
   Web of Science ®Google Scholar
• GersterJCAcute polyarthritis related to once-weekly alendronate in a woman with osteoporosisJ Rheumatol20043182983015095748
   PubMed Web of Science ®Google Scholar
• PazianasMCompstonJHuangCLAtrial fibrillation and bisphosphonate therapyJ Bone Miner Res20102521020091928
   PubMed Web of Science ®Google Scholar
• HeckbertSRLiGCummingsSRUse of alendronate and risk of incident atrial fibrillation in womenArch Intern Med200816682683118443257
   PubMedGoogle Scholar
• ReckerRRLewieckiEMMillerPDSafety of bisphosphonates in the treatment of osteoporosisAm J Med.2009122Suppl 2AS22S3219187809
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationThe FDA safety information and adverse event reporting program Available at: www.fda.gov/medwatch/safety/2008/safety08.htm#bisphosphonates2Accessed March 7, 2010
   Google Scholar
• BoonenSSellmeyerDELippunerKfor the HORIZON Pivotal Fracture TrialRenal safety of annual zoledronic acid infusions in osteoporotic postmenopausal womenKidney Int20087464164818509324
   PubMed Web of Science ®Google Scholar
• OdvinaCVZerwekhJERaoESSeverely suppressed bone turnover: A potential complication of alendronate therapyJ Clin Endocrinol Metab2005901294130115598694
   PubMed Web of Science ®Google Scholar
• VisekrumaMWilsonDMcKienanFESeverely suppressed bone turnover and atypical skeletal fragilityJ Clin Endocrinol Metab2008932948295218522980
   PubMed Web of Science ®Google Scholar
• GohSKYangKYKohJSSubtrochanteric insufficiency fractures in patients on alendronate therapy: A cautionJ Bone Joint Surg (Br)20078934935317356148
   PubMed Web of Science ®Google Scholar
• NeviaserASLaneJMLenartBALow energy femoral shaft fractures associated with alendronate useJ Orthop Trauma20082234635018448990
   PubMed Web of Science ®Google Scholar
• KwekEBGoshSKKohJSAn emerging pattern of subtrochanteric stress fractures: A long term complication of alendronate therapyInjury200839231234
   Web of Science ®Google Scholar
• SilvermanSLLandesbergLOsteonecrosis of the jaw and the role of bisphosphonates: A critical reviewAm J Med.2009122suppl 2AS33S4519187811
   PubMed Web of Science ®Google Scholar
• EdwardsBJHellsteinJWJacobsenPLAmerican Dental Association Council on Scientific AffairsDental management of patients receiving oral bisphosphonate therapy – expert panel recommendations Available from: http://docs.google.com/viewer?a=v&q=cache:REeDi89n3XkJ:flouridation.org/prof/resources/topics/topics_osteonecrosis_bisphosphonate_report.pdf+dental+management+of+patients+receiving+bisphosphonate+therapy&hl=en&gl=us&pid=bl&srcid=ADGEESjBbRbOksrGZtIqeGAgZP8Tad_tR9KwQb_YQa4wM0k1Bb1YuQB0z_MAR-UKG9o2ZK5HfascML1GoPAQDCWYuwgmeG1iu5Cz-YRjZi1y0M292RY2VfpM1y3xuzH1uE2L_-vD36Fn&sig=AHIEtbTxiSSidA6ORxdjmiBtb6esNOa5RQAccessed March 7, 2010
   Google Scholar
• KhoslaSBurrDCauleyJfor the American Society for Bone and Mineral ResearchBisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral ResearchJ Bone Miner Res2007221479149117663640
   PubMed Web of Science ®Google Scholar
• Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaw, American Association of Oral and Maxillofacial SurgeonsAmerican Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jawsJ Oral Maxillofac Surg20076536937617307580
   PubMed Web of Science ®Google Scholar
• DemerjianNBollaGSpreuxASevere oral ulcerations induced by alendronateClin Rheumatol20001834935010468180
   PubMed Web of Science ®Google Scholar
• KrasagakisKKruger-KrasagakisSIoannidouDToscaAChronic erosive and ulcerative oral lesions casued by incorrect administration of alendronateJ Am Acad Dermatol20045065165215034526
   PubMed Web of Science ®Google Scholar
• de GroenPCLubbeDFHirschLJEsophagitis associated with the use of alendronateN Engl J Med1996335101610218793925
   PubMed Web of Science ®Google Scholar
• BauerDCBlackDEnsrudKUpper gastro-intestinal tract safety profile of alendronate. The Fracture Intervention TrialArch Intern Med200016051752510695692
   PubMed Web of Science ®Google Scholar
• MarxRRESawatariYFortinMBroumandVBisphosphonate-induced exposed bone of the jaws: Risk factors, recognition, prevention and treatmentJ Oral Maxillofac Surg2005631567157516243172
   PubMed Web of Science ®Google Scholar
• KimmelDBMechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonatesJ Dent Res2007861022103317959891
   PubMed Web of Science ®Google Scholar
• WooSBHellsteinJWKalmarJRNarrative [corrected] review: Bisphosphonates and osteonecrosis of the jawAnn Intern Med200614475376116702591
   PubMed Web of Science ®Google Scholar
• RuggieroSLGralowJMarxREPractical guidelines for the prevention, diagnosis and treatment of osteonecrosis of the jaw in patients with cancerJ Oncol Pract2006271420871729
   PubMedGoogle Scholar
• GrbicJTLandesbergRLinSQIncidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trialJ Am Dent Assoc2008139324018167382
   PubMed Web of Science ®Google Scholar
• MarxRECilloJEJrUlloaJJOral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTx testing, prevention and treatmentJ Oral Maxillofac Surg2007652397241018022461
   PubMed Web of Science ®Google Scholar
• LehrerSMontazemARamanathanLNormal serum bone markers in bisphosphonate-induced osteonecrosis of the jawsOral Surg Oral Med Oral Pathol Oral Radiol Endod200810638939118554944
   PubMed Web of Science ®Google Scholar
• MavrokokkiTChengASteinBNature and frequency of bisphosphonate-associated osteonecrosis of the jaws in AustraliaJ Oral Maxillofac Surg20076541542317307586
   PubMed Web of Science ®Google Scholar
• PalaskaPKCartsosVZavrasABisphosphonates and time to osteonecrosis developmentOncologist2009141154116619897878
   PubMed Web of Science ®Google Scholar
• American Dental Association Council on Scientific AffairsDental management of patients receiving oral bisphosphonate therapy. Expert Panel recommendationsJ Am Dent Assoc20061371144115016873332
   PubMed Web of Science ®Google Scholar
• ASBMR Task Force on Bisphosphonate-Associated ONJBisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral ResearchJ Bone Miner Res2007221479149117663640
   PubMed Web of Science ®Google Scholar
• BanalFBriotKAyoubGUnilateral anterior uveitis complicating zoledronic acid therapy in prostate cancer [letter to the editor]J Rheumatol2008352458245919040323
   PubMed Web of Science ®Google Scholar
• BendersonDKarakunnelDKathuriaSBadrosAScleritis complicating zoledronic acid infusionClin Lymphoma Myeloma Leuk20067145147
   Web of Science ®Google Scholar
• El SaghirNSOtrockZKBleikJHUnilateral anterior uveitis complicating zoledronic acid therapy in breast cancerBMC Cancer2005515616332258
   PubMed Web of Science ®Google Scholar
• KilickapSOzdamarYAltundagMKA case report: Zoledronic acid induced uveitisMed Oncol20082523824018488162
   PubMed Web of Science ®Google Scholar
• LeungSAsharBHMillerRGBisphosphonate associated scleritis: A case report and reviewSouth Med J20059873373516108245
   PubMed Web of Science ®Google Scholar
• ProcianoyFProcianoyEOrbital inflammatory disease secondary to a single-dose administration of zoledronic acid for treatment of postmenopausal osteoporosisOsteoporos Int2010211057105819859646
   PubMed Web of Science ®Google Scholar
• BerrutiATucciMGeneraliDManagement of the side-effects of intravenous bisphosphonates: Targeting the serum parathyroid hormone elevationAnn Oncol2006171854185516936183
   PubMed Web of Science ®Google Scholar